IP Library Granted Patent US 10,016,409
Granted Patent B2
US 10,016,409 · App. 15/650,554 · Granted Jul 10, 2018

Method for improving interstitial flow

Inventors: Masafumi Ihara (Hyogo, JP); Takakuni Maki (Hyogo, JP); Akihiko Taguchi (Hyogo, JP)
Assignee: FOUNDATION FOR BIOMEDICAL RESEARCH AND INNOVATION AT KOBE
A61K31/4709A61K9/0019A61K9/14C07D401/12
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,016,409
App. No.
15/650,554
Granted
Jul 10, 2018
Kind
B2
Abstract

Provided is a prophylactic and/or therapeutic drug for mild cognitive impairment, which can improve interstitial flow in cerebral blood vessel and the like to achieve sufficient clearance of harmful proteins accumulated in the brain. The prophylactic and/or therapeutic drug includes 6-[4-(1-cyclohexyl-1H-tetrazole-5-yl)butoxy]3,4-dihydrocarbostyril or a salt thereof as an active ingredient. The prophylactic and/or therapeutic drug can improve a flow of interstitial fluid around blood vessels in a drainage pathway to excrete harmful proteins. The prophylactic and/or therapeutic drug for mild cognitive impairment may take the form of a pharmaceutical product for oral administration, a liquid pharmaceutical product for oral administration, or an injectable preparation. The prophylactic and/or therapeutic drug for mild cognitive impairment can be used for the prevention and/or treatment of cerebral amyloid angiopathy, and can also be used for improvement of Lewy body disease, Down's syndrome, or macular degeneration.

Claims (6)

1. A method for improving interstitial flow, the method comprising:

administering an effective amount of an agent comprising cilostazol to a patient.

2. The method of claim 1 , the method comprising:

improving interstitial flow flowing in cerebral blood vessel wall.

3. The method of claim 1 , wherein the patient is a mild cognitive impairment patient.

4. The method of claim 1 , wherein the patient has mini-metal state examination scores from 22 to 26.

Assignments (1)
CHANGE OF NAME Recorded May 30, 2018
From: FOUNDATION FOR BIOMEDICAL RESEARCH AND INNOVATION
To: FOUNDATION FOR BIOMEDICAL RESEARCH AND INNOVATION AT KOBE
Reel/Frame 046808/0793 →
Priority Claims (2)
JP 2012-135906 · Jun 15, 2012 · national
JP 2012-223580 · Oct 5, 2012 · national
Continuity (3)
Continuation 14860057 · Sep 21, 2015
Continuation 14407692
Related Publication 20170312265A1 · Nov 2, 2017